Mr. Bent U. Frandsen MSc
Chief Executive Officer
Biography unavailable
ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
STO:EXPRS2
Price:
1.04
SEK
5.05%
Market Cap:
kr24.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
SE |
|
MercadoLibre Inc
BMV:MELIN
|
UY |
|
Stingray Group Inc
TSX:RAY.A
|
CA |
|
Fraser and Neave Ltd
SGX:F99
|
SG |
|
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
AU |
|
A
|
Ansell Ltd
DUS:PD1A
|
AU |
|
Nikkiso Co Ltd
F:NKO
|
JP |
|
Subsea 7 SA
OSE:SUBC
|
UK |
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
US |
|
M
|
MillerKnoll Inc
SWB:MHR
|
US |
|
JD Sports Fashion PLC
LSE:JD
|
UK |
|
Dome Gold Mines Ltd
ASX:DME
|
AU |
|
A
|
AsiaStrategy
NASDAQ:SORA
|
HK |
|
Central Japan Railway Co
TSE:9022
|
JP |
|
S
|
Silgan Holdings Inc
NYSE:SLGN
|
US |
|
Gefran S.p.a
F:GF7
|
IT |
|
J
|
J. Front Retailing Co Ltd
TSE:3086
|
JP |
|
Kingfa Science and Technology (India) Ltd
NSE:KINGFA
|
IN |
|
M
|
Maple Gold Mines Ltd
OTC:MGMLF
|
CA |
|
P
|
Parker-Hannifin Corp
F:PAR
|
US |
|
Fideicomiso Irrevocable No F/1401
OTC:FBASF
|
MX |
|
S
|
Song Da No 9 JSC
VN:SD9
|
VN |
|
Mesoblast Ltd
ASX:MSB
|
AU |
|
E
|
Enel SpA
OTC:ESOCF
|
IT |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Biotechnology
- Headquarters
- Sweden SE
- Employees
- 29
- IPO date
- Jul 29, 2016
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
Continue EXPRS2 Research
Other ExpreS2ion Biotech Holding AB listings: